In a recent study, the annual change rate of NFL allowed for separation of carriers of the APOE ε4 allele, a risk factor for AD, from non-carriers 16 years before the expected onset of symptoms [94], rendering NFL as a possible biomarker for preclinical AD. This evidence concerns the gene NEFL and Alzheimer disease.